☆ 4.6 Article

Risk of outcomes in a Spanish population with chronic kidney disease

CLINICAL KIDNEY JOURNAL (2022)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Epidemiology and treatment of heart failure in Spain: the HF-PATHWAYS study

Antoni Sicras-Mainar et al.

Summary: This study describes the epidemiology and treatment of a large contemporary cohort of heart failure patients. The results show that the epidemiological data on heart failure remained stable during the study period, with a lower prevalence than reported in non-population-based studies. There is room for improvement in the optimization of medical treatment for heart failure patients.

REVISTA ESPANOLA DE CARDIOLOGIA (2022)

Add to Collection

Review Cardiac & Cardiovascular Systems

Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin

Ricardo Fontes-Carvalho et al.

Summary: The cardiovascular and renal systems are closely interconnected, forming the cardiorenal continuum, where interventions at any point along the continuum may disrupt the pathophysiological cascade. The use of SGLT2 inhibitors has shown to reduce cardiovascular and kidney outcomes, benefiting both diabetic and non-diabetic patients.

EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY (2022)

Add to Collection

Editorial Material Pharmacology & Pharmacy

An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia

Chandan Takkar et al.

Summary: Hyperkalemia, defined as a serum potassium level > 5.0 mEq/l, is common in patients with CKD, DM, and HF, especially those treated with RAAS inhibitors or potassium-sparing diuretics. Two new promising agents, SZC and Patiromer, have revolutionized the approach to treating hyperkalemic patients, allowing for the continued use of RAAS inhibitors for renal and cardiac protection. Recent clinical trials have shown that SZC effectively lowers serum potassium and maintains normokalemia in most patients, with minimal adverse effects.

EXPERT OPINION ON PHARMACOTHERAPY (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes A Meta-analysis

Darren K. McGuire et al.

Summary: SGLT2 inhibitors were found to reduce the risk of major adverse CV events and showed significant heterogeneity in associations with CV death. The most consistent benefit of this class of drugs was a reduction in risk for heart failure and kidney outcomes, with heart failure risk reduction being the most consistent observation across the trials.

JAMA CARDIOLOGY (2021)

Add to Collection

Review Medicine, Research & Experimental

Costs and Healthcare Resource Use Associated with Risk of Cardiovascular Morbidity in Patients with Chronic Kidney Disease: Evidence from a Systematic Literature Review

Oliver Darlington et al.

Summary: This study evaluated the risks of cardiovascular morbidity and mortality in patients with chronic kidney disease, finding that the risk of adverse clinical outcomes increases with the severity of CKD and albuminuria. This is associated with substantial additional costs and healthcare resource utilization, highlighting the importance of early diagnosis and proactive management of CKD to reduce the burden on healthcare resources.

ADVANCES IN THERAPY (2021)

Add to Collection

Article Medicine, Research & Experimental

Clinical Outcomes and Healthcare Resource Utilization in a Real-World Population Reflecting the DAPA-CKD Trial Participants

Tope Olufade et al.

Summary: The study observed the impact of different UACR levels on adverse renal and cardiovascular outcomes in patients with chronic kidney disease, finding that patients with higher UACR levels had higher rates of adverse outcomes. Furthermore, the DAPA-CKD-like cohort showed significant differences in healthcare costs, hospital admission rates, and outpatient specialist visit rates compared to the lowest UACR category.

ADVANCES IN THERAPY (2021)

Add to Collection

Article Medicine, General & Internal

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

Deepak L. Bhatt et al.

Summary: The trial involving 10,584 patients with diabetes and chronic kidney disease showed that sotagliflozin resulted in fewer deaths from cardiovascular causes, hospitalizations for heart failure, and urgent visits for heart failure compared to placebo. However, there were adverse events such as diarrhea, mycotic infections, and diabetic ketoacidosis associated with sotagliflozin.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease

John J. V. McMurray et al.

Summary: Dapagliflozin reduces the risk of kidney failure, death from cardiovascular causes or hospitalization for heart failure, and prolongs survival in people with chronic kidney disease, independently of the presence of concomitant cardiovascular disease, regardless of whether they have type 2 diabetes.

CIRCULATION (2021)

Add to Collection

Review Medicine, General & Internal

Clinical Management of Hyperkalemia

Biff F. Palmer et al.

Summary: Hyperkalemia is a common electrolyte abnormality that requires personalized monitoring and management. Further research is needed to promote more effective treatment of hyperkalemia.

MAYO CLINIC PROCEEDINGS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Sodium-glucose transporter 2 inhibitors for renal and cardiovascular protection in US adults with type 2 diabetes: Impact of the 2020 KDIGO clinical practice guidelines

Stefano Ciardullo et al.

Summary: According to the 2020 KDIGO guidelines, 35.3% of T2D patients in the US (approximately 8.96 million) should be treated with SGLT2-i. Additionally, 2.9-10.1% (approximately 0.75-2.55 million) met the inclusion criteria for dedicated kidney outcome trials, which focused on a population with proteinuria.

PHARMACOLOGICAL RESEARCH (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

Hiddo J. L. Heerspink et al.

Summary: Dapagliflozin significantly reduces all-cause mortality in CKD patients, predominantly by reducing non-cardiovascular deaths. The benefits are consistent across pre-specified subgroups and driven largely by reductions in deaths due to infections and malignancies.

EUROPEAN HEART JOURNAL (2021)

Add to Collection

Article Cardiac & Cardiovascular Systems

Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes A Prespecified Secondary Analysis of a Randomized Clinical Trial

Thomas A. Zelniker et al.

Summary: The study showed that the relative risk reduction for cardiovascular events with dapagliflozin is consistent across different eGFR and UACR groups, with the greatest absolute benefit observed among patients with both reduced eGFR and albuminuria.

JAMA CARDIOLOGY (2021)

Add to Collection

Article Health Care Sciences & Services

Costs and healthcare utilisation of patients with chronic kidney disease in Spain

Carlos Escobar et al.

Summary: Between 2015 and 2019, the costs of patients with chronic kidney disease (CKD) in Spain were high, with cardiovascular hospitalizations being the key determinant. Medication costs accounted for only a small proportion of total CKD costs. Costs associated with cardiovascular hospitalizations, cardiovascular and diabetic medications, as well as hospitalization and mortality rates, all decreased over the study period.

BMC HEALTH SERVICES RESEARCH (2021)

Add to Collection

Article Urology & Nephrology

Epidemiology clinical profile, management, and two-year risk complications among patients with chronic kidney disease in Spain

Carlos Escobar et al.

Summary: In Spain, the CKD population is characterized by older age and common comorbidities such as diabetes and heart failure. Cardiovascular and renal outcomes are frequent, indicating a need for improvement in CKD management through the use of drugs with proven cardiovascular and renal benefits.

NEFROLOGIA (2021)

Add to Collection

Article Urology & Nephrology

Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment

Ian H. de Boer et al.

KIDNEY INTERNATIONAL (2020)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin in Patients with Chronic Kidney Disease

Hiddo J. L. Heerspink et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, General & Internal

Medical Costs Associated with Severity of Chronic Kidney Disease in Type 2 Diabetes Mellitus in Singapore

Gwyneth J. Lim et al.

ANNALS ACADEMY OF MEDICINE SINGAPORE (2020)

Add to Collection

Article Endocrinology & Metabolism

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

David C Wheeler et al.

Lancet Diabetes & Endocrinology (2020)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

V. Perkovic et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Editorial Material Transplantation

A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases

Kitty J. Jager et al.

NEPHROLOGY DIALYSIS TRANSPLANTATION (2019)

Add to Collection

Article Endocrinology & Metabolism

Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial

Ofri Mosenzon et al.

LANCET DIABETES & ENDOCRINOLOGY (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Urology & Nephrology

Chronic kidney disease in Spain: Prevalence and impact of accumulation of cardiovascular risk factorsN

Manuel Gorostidi et al.

NEFROLOGIA (2018)

Add to Collection

Review Medicine, General & Internal

Chronic kidney disease

Angela C. Webster et al.

LANCET (2017)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Cardiac & Cardiovascular Systems

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC

Piotr Ponikowski et al.

EUROPEAN JOURNAL OF HEART FAILURE (2016)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Article Medicine, General & Internal

Chronic kidney disease: global dimension and perspectives

Vivekanand Jha et al.

LANCET (2013)

Add to Collection

Article Endocrinology & Metabolism

Evidence for a dose effect of renin-angiotensin system inhibition on progression of microalbuminuria in Type 2 diabetes: a meta-analysis

C. L. Blacklock et al.

DIABETIC MEDICINE (2011)

Add to Collection

Article Medicine, General & Internal

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

EJ Lewis et al.

NEW ENGLAND JOURNAL OF MEDICINE (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.